BioSpace News Archive

The report highlights trends prevailing in the global implantable sensor market, and the factors driving and restraining the market growth.

The market growth is mainly attributed to the increasing research and development in the pharmaceuticals industry, and surging incidence of infectious diseases.

The American Diabetes Association® (ADA) is kicking off the virtual 81st Scientific Sessions tomorrow and will feature five COVID-19 Symposia, highlighting cutting-edge science and the latest diabetes developments learned during the initial phases of the pandemic.

OSE Immunotherapeutics announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.

German-based joimax®, the market leader in technologies and training methods for full-endoscopic and minimally invasive spinal surgery, is excited to announce the global launch of its new generation Shrill®, the Shaver Drill System.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that following its receipt of EUA approval from COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) under registration number “OFICIO: CAS/10720/2021”, it is establishing a local “Sorrento Mexico Ltd” subsidiary to manage commercial operations in Mexico.

Invivoscribe, a global leader in precision diagnostics, has announced the launch of an Immune Biomarker Discovery grant program, focused on supporting development, validation and deployment of novel applications for use of their distributed LymphoTrack® NGS products and bioinformatics software.

Concert Genetics has released its comprehensive genetic test identification system for use in the market, enabling a level of automation in test ordering, coverage, payment and clinical decision support never before possible, the company announced today.

Seraphina Therapeutics, Inc., a health and wellness company dedicated to advancing global health through the discovery and development of beneficial essential fatty acids and micronutrients, today announced that it has achieved Generally Recognized as Safe (GRAS) status for its revolutionary FA15™ ingredient. FA15™ has been approved as a food ingredient that can be used daily, up to 245 mg per day.

Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain held various leadership positions for the British pharmaceutical group GlaxoSmithKline, most recently as Global President Pharmaceuticals and Vaccines for five years